From the Journals

Psilocybin Beats Nicotine Patch in Smoking Trial

A single psilocybin dose outperforms standard nicotine replacement, opening a new front in one of medicine’s most intractable problems.

Share

  • 1

    - Study published in JAMA Network Open highlights potential of psilocybin for smoking cessation. - Participants: 82 adult smokers with prior failed quit attempts. - Psilocybin group had 41% abstinence at 6 months, nicotine patch group had 10%. - Focus on cognitive behavioral therapy (CBT) alongside treatments. - Unblinded design raises questions about expectancy effects. - Call for larger trials to validate findings and assess optimal dosing.

Original Source(s)

Psilocybin Beats Nicotine Patch in Smoking Trial

A single psilocybin dose outperforms standard nicotine replacement, opening a new front in one of medicine’s most intractable problems.

  • by Kerri Miller

  • March 10, 2026

  • 6 min

Related Content

Singing Program Feasible After Pulmonary Rehabilitation

Study finds 12-week singing intervention feasible following pulmonary rehabilitation, supporting larger trial.

COPD Clinical Trials at Temple Lung Center

Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity, and many patients continue to experience symptoms despite optimal therapy. As one of the world’s largest and most experienced COPD research programs, the Temple Lung Center offers access to clinical trials evaluating new pharmacologic, device-based, and comprehensive treatment approaches.

  • by

  • February 19, 2026

  • 2 min
Chronic Cough Despite Normal Workup

Researchers describe diagnostic evaluation and management considerations when standard testing fails to identify the cause of persistent cough.